| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to oncology, and can be applied as adaptation potential assessment method. Patient examination is performed, the following indicators are determined: lymphocyte index (LI), adaptation index (total index of non-specific resistance, TINR), immunoreactivity index (IRI). Further adaptation coefficients (K) for each indicator are defined on the basis of obtained data. Namely, in LI system K is (-1.3) for marker up to 0.4, (-1.2) for marker within 0.41-0.5, (-1.1) for marker within 0.51-0.6, (+1) for marker within 0.61-0.7, (+1) for marker within 0.71-0.8, (+1.2) for marker within 0.81-1.0, (+1.3) for marker over 1.0. In TINR system K is (-1.3) for marker up to 0.3, (-1.2) for marker within 0.31-0.5, (-1.1) for marker within 0.51-0.7, (+1) for marker within 0.71-0.9, (+1.1) for marker within 0.91-1.1, (+1.2) for marker within 1.11-1.3, (+1.3) for marker over 1.3. In IRI system K is (-1.3) for marker up to 3.0, (-1.2) for marker within 3.01-5.0, (-1.1) for marker within 5.01-7.0, (+1) for marker within 7.01-9.0, (+1.1) for marker within 9.01-11.0, (+1.2) for marker within 11.01-13.0, (+1.3) for marker over 13.0. Total adaptation potential indicator (TAPI) for breast cancer patients is obtained by aggregation of K of all indicators. For TAPI under 1 adaptation potential is considered low, for TAPI within 1 to 3 adaptation potential is considered satisfactory, for TAPI over 3 adaptation potential is considered high. ^ EFFECT: possible assessment of adaptation potential for breast cancer patients at various treatment stages for assessment of treatment efficiency and further forecast using standard paraclinic tests. ^ 2 tbl, 2 ex |
